Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.25
+0.17 (2.80%)
At close: Jun 18, 2026, 4:00 PM EDT
6.23
-0.02 (-0.32%)
After-hours: Jun 18, 2026, 4:32 PM EDT
Gyre Therapeutics Employees
Gyre Therapeutics had 625 employees as of December 31, 2025. The number of employees increased by 46 or 7.94% compared to the previous year.
Employees
625
Change (1Y)
46
Growth (1Y)
7.94%
Revenue / Employee
$187,278
Profits / Employee
-$10,179
Market Cap
571.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 625 | 46 | 7.94% |
| Dec 31, 2024 | 579 | -14 | -2.36% |
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Ginkgo Bioworks Holdings | 485 |
| ProKidney | 231 |
| Prime Medicine | 146 |
| BridgeBio Oncology Therapeutics | 106 |
| AgomAb Therapeutics NV | 62 |
| Tectonic Therapeutic | 60 |
| Crescent Biopharma | 55 |
GYRE News
- 11 days ago - Gyre Therapeutics Transcript: AGM 2026 - Transcripts
- 19 days ago - Gyre Therapeutics Slides: Corporate presentation - Filings
- 25 days ago - Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm - Newsfile Corp
- 5 weeks ago - Gyre Therapeutics announces China NMPA acceptance of F351 NDA - TheFly
- 5 weeks ago - Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year - TheFly
- 6 weeks ago - Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Earnings release: Q1 2026 - Filings